1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023

Summary

Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

Originally developed as a cancer therapy, MTX has become the leading DMARD in most countries because of its rapid onset of action and low cost. MTX is an antineoplastic antimetabolite with immunosuppressant actions. Its use for the treatment of RA began in the 1970s, as it had been shown to sustain benefits for at least 50% of RA patients. MTX is an antagonist of folic acid metabolism, and its effects in inflammatory diseases may be secondary to the induction of adenosine release and the inhibition of polyamines.

Scope

- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Methotrexate including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Methotrexate for the top 10 countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of Methotrexate performance.
- Obtain sales forecast for Methotrexate from 2013-2023 in top 10 countries (the US, France, Germany, Italy, Spain, the UK and Japan, Australia, China and India).

Table Of Contents

Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023
1 Table of Contents
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.2 Symptoms 19
3.3 Prognosis 20
3.4 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis and Treatment Overview 21
4.1.1 Diagnosis 21
4.1.2 Treatment Guidelines 23
4.1.3 Leading Prescribed Drugs for the Treatment of RA 32
4.1.4 Clinical Practice 33
5 Competitive Assessment 39
5.1 Overview 39
6 Methotrexate (Numerous Brands) 41
6.1 Overview 41
6.2 Efficacy 42
6.3 Safety 43
6.4 SWOT Analysis 43
6.5 Forecast 44
7 Appendix 45
7.1 Bibliography 45
7.2 Abbreviations 48
7.3 Methodology 51
7.4 Forecasting Methodology 51
7.4.1 Diagnosed RA Patients 51
7.4.2 Percentage of Drug-Treated Patients 52
7.4.3 General Pricing Assumptions 52
7.4.4 Individual Drug Assumptions 53
7.4.5 Generic and Biosimilar Erosion 54
7.5 Primary Research - KOLs Interviewed for This Report 55
7.6 Primary Research - Prescriber Survey 57
7.7 About the Authors 58
7.7.1 Analyst 58
7.7.2 Reviewer 58
7.7.3 Therapy Area Director 59
7.7.4 Global Head of Healthcare 59
7.8 About GlobalData 60
7.9 Disclaimer 60

1.1 List of Tables

Table 1: Symptoms of RA 19
Table 2: 1987 ACR Diagnostic Criteria for RA 22
Table 3: 2010 ACR/EULAR Diagnostic Criteria for RA 23
Table 4: Treatment Guidelines for RA Used by Each Country in the 10MM 25
Table 5: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 28
Table 6: EULAR 2013 Criteria for RA Remission 29
Table 7: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 33
Table 8: Leading Branded Treatments for RA 2014 40
Table 9: Product Profile - MTX 42
Table 10: MTX SWOT Analysis, 2014 43
Table 11: Global Sales Forecasts ($m) for MTX, 2013-2023 44
Table 12: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 57

1.2 List of Figures

Figure 1: Normal Synovial Joint and Synovial Joint with RA 15
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 18
Figure 3: Disease Management Flowchart for Early RA - ACR 2012 29
Figure 4: Disease Management Flowchart for Established RA - ACR 2012 30
Figure 5: Flowchart for the Management of RA - EULAR 2013 31

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025 Summary Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung ...

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Myelofibrosis - Opportunity Analysis and Forecasts to 2025 Summary Myelofibrosis (MF) is a rare blood disorder, which is characterized by bone marrow fibrosis. Currently, there is ...

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

OpportunityAnalyzer: Endometriosis - Opportunity Analysis and Forecast to 2025 Summary Endometriosis is an estrogen-dependent, chronic, inflammatory disease characterized by the appearance and growth of ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.